Acumen Pharmaceuticals, Inc.
ABOS
$1.36
-$0.05-3.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -99.40% | -93.61% | -125.22% | -129.72% | -76.89% |
| Total Depreciation and Amortization | 4.44% | 2.27% | 12.82% | 12.50% | -15.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,436.26% | 92.09% | -19.90% | 56.18% | -85.09% |
| Change in Net Operating Assets | 66.67% | -81.02% | 35.79% | 525.28% | 382.23% |
| Cash from Operations | -92.40% | -91.06% | -227.34% | -90.59% | -41.77% |
| Capital Expenditure | -80.00% | -618.18% | 100.00% | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.09% | 412.97% | 160.79% | 88.99% | 240.78% |
| Cash from Investing | 2.08% | 411.74% | 160.78% | 88.99% | 240.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.53% | -- | -100.00% | -- |
| Repurchase of Common Stock | -- | -128.13% | 97.69% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -128.97% | 11.72% |
| Cash from Financing | 100.00% | -100.51% | -100.03% | -100.03% | 11.72% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -68.37% | 72.60% | 108.71% | -294.70% | 2,899.73% |